LMAT · Lemaitre Vascular Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LMAT
this stock
Lemaitre Vascular Inc
|
$1.84B | -0.5% | +13.5% | 28.2 | 7.0% |
|
ISRG
Intuitive Surgical Inc
|
$129.55B | -35.3% | +20.5% | 42.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$50.32B | — | +8.2% | — | 3.4% |
|
MDLN
Medline Inc.
|
$48.11B | -12.9% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$34.08B | -10.5% | +10.5% | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LMAT | +0.3% | -1.0% | -27.2% | +0.5% | -0.5% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +0.2% | -0.6% | -42.3% | +0.1% | -13.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.